Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus aspirin added to clopidogrel or ticagrelor after acute coronary syndrome
NL-OMON42240Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rivaroxaban, aspirin, clopidogrel and ticagrelor in acute coronary syndrome (ACS), myocardial infarction (MI) and unstable angina (2 arms), sponsored by Janssen Pharmaceutical. Started Mar 2015; status: active, not recruiting.
02
Drugs
rivaroxabanaspirinclopidogrelticagrelor
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on NL-OMON42240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42240.